Beta-defensin 113

Also known as: Beta-defensin 13, Defensin, beta 113, DEFB113, Q30KQ7

Beta-defensin 113 (DEFB113) is a member of the beta-defensin family, a group of antimicrobial peptides primarily expressed in epithelial tissues. Its proposed mechanism of action involves direct interaction with bacterial cell membranes, leading to membrane disruption and subsequent microbial killing. This activity is typical of defensins, which are cationic and amphipathic, allowing them to bind to negatively charged bacterial surfaces and form pores or destabilize the lipid bilayer. Currently, DEFB113 is classified as an experimental peptide with no published research studies indexed in PubMed. Its functional characterization is inferred from sequence homology to other beta-defensins, such as DEFB1 and DEFB4, which have demonstrated broad-spectrum antibacterial activity. No specific in vitro or in vivo data are available to confirm its antimicrobial efficacy, target specificity, or expression patterns in human tissues. Given the absence of direct experimental evidence, the clinical relevance of DEFB113 remains undefined. It has not been investigated in therapeutic contexts, and no translational applications have been proposed. Further research is required to validate its biological activity and potential utility in infectious disease or immune modulation. For research purposes only — not medical advice.

Key data

Mechanism of action

Has antibacterial activity

Frequently asked questions

Related peptides